Literature DB >> 22025213

Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.

Kelli Elizabeth Valdez1, Fang Fan, William Smith, D Craig Allred, Daniel Medina, Fariba Behbod.   

Abstract

Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. The current recognition that DCIS lesions exhibit inter- and intra-lesion diversity suggests that the process of evolution to invasive breast cancer is more complex than previously recognized. Here we demonstrate the reproducible growth of primary DCIS cells derived from patient's surgical and biopsy samples by the mouse intraductal (MIND) model. MIND involves injection of cells into the NOD-SCID IL2Rgamma$^{{\rm{null}}}$ (NSG) mouse mammary ducts. Twelve (eight unique and four repeats) DCIS and two atypical hyperplasia specimens, heterogeneous with respect to biomarker expression and histology, were injected into 48 mouse mammary glands and analysed for successful xenotransplantation. Overall, 14/34 and 11/14 MIND xenotransplanted glands contained human DCIS and atypical hyperplastic cells, respectively, after 8 weeks, which formed single and multi-layered epithelium inside the ducts, and were heterogeneous with respect to expression of human cytokeratins, oestrogen receptor α (ER), and HER2. ER protein expression was recapitulated in MIND xenografts at ratios similar to the corresponding patient biopsies. In both patient biopsies and corresponding MIND xenografts, HER2 protein expression and nuclear HER2 gene overexpression were restricted to the DCIS lesions and were not found in the surrounding stroma or normal ducts. The xenografted DCIS lesions recapitulate the pathology and heterogeneity of human disease, thus providing a powerful tool for the characterization of the distinct cellular and molecular basis of inter- and intra-tumoural heterogeneity and the processes of DCIS to early invasive breast cancer progression.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025213      PMCID: PMC3496769          DOI: 10.1002/path.2969

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  32 in total

1.  Gene expression profiles of human breast cancer progression.

Authors:  Xiao-Jun Ma; Ranelle Salunga; J Todd Tuggle; Justin Gaudet; Edward Enright; Philip McQuary; Terry Payette; Maria Pistone; Kimberly Stecker; Brian M Zhang; Yi-Xiong Zhou; Heike Varnholt; Barbara Smith; Michelle Gadd; Erica Chatfield; Jessica Kessler; Thomas M Baer; Mark G Erlander; Dennis C Sgroi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-24       Impact factor: 11.205

2.  A SAGE (serial analysis of gene expression) view of breast tumor progression.

Authors:  D A Porter; I E Krop; S Nasser; D Sgroi; C M Kaelin; J R Marks; G Riggins; K Polyak
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

3.  Proteomics of human breast ductal carcinoma in situ.

Authors:  Julia D Wulfkuhle; Dennis C Sgroi; Henry Krutzsch; Kelley McLean; Kelly McGarvey; Melodie Knowlton; She Chen; Hongjun Shu; Aysegul Sahin; Raffael Kurek; Diethelm Wallwiener; Maria J Merino; Emanuel F Petricoin; Yingming Zhao; Patricia S Steeg
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

4.  A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland.

Authors:  C Schulze-Garg; J Löhler; A Gocht; W Deppert
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

Review 5.  What is the malignant nature of human ductal carcinoma in situ?

Authors:  Virginia Espina; Lance A Liotta
Journal:  Nat Rev Cancer       Date:  2010-12-02       Impact factor: 60.716

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 7.  Molecular markers and therapeutic targets in ductal carcinoma in situ.

Authors:  Gary P Boland; W Fiona Knox; Nigel J Bundred
Journal:  Microsc Res Tech       Date:  2002-10-01       Impact factor: 2.769

Review 8.  Xenograft models of premalignant breast disease.

Authors:  F R Miller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 9.  Ductal carcinoma in situ, complexities and challenges.

Authors:  Gregory D Leonard; Sandra M Swain
Journal:  J Natl Cancer Inst       Date:  2004-06-16       Impact factor: 13.506

10.  Molecular markers in ductal carcinoma in situ of the breast.

Authors:  Dale Porter; Jaana Lahti-Domenici; Aparna Keshaviah; Young Kyung Bae; Pedram Argani; Jeffrey Marks; Andrea Richardson; Amiel Cooper; Robert Strausberg; Gregory J Riggins; Stuart Schnitt; Edward Gabrielson; Rebecca Gelman; Kornelia Polyak
Journal:  Mol Cancer Res       Date:  2003-03       Impact factor: 5.852

View more
  44 in total

Review 1.  Intra-mammary ductal transplantation: a tool to study premalignant progression.

Authors:  Daniel Medina; David G Edwards; Frances Kittrell; Sangjun Lee; D Craig Allred
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-06-12       Impact factor: 2.673

Review 2.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

3.  BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression.

Authors:  Hanan S Elsarraj; Yan Hong; Darlene Limback; Ruonan Zhao; Jenna Berger; Stephanie C Bishop; Aria Sabbagh; Linzi Oppenheimer; Haleigh E Harper; Anna Tsimelzon; Shixia Huang; Susan G Hilsenbeck; Dean P Edwards; Joseph Fontes; Fang Fan; Rashna Madan; Ben Fangman; Ashley Ellis; Ossama Tawfik; Diane L Persons; Timothy Fields; Andrew K Godwin; Christy R Hagan; Katherine Swenson-Fields; Cristian Coarfa; Jeffrey Thompson; Fariba Behbod
Journal:  NPJ Breast Cancer       Date:  2020-04-24

Review 4.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

5.  Progesterone and Breast Cancer: an NCI Workshop Report.

Authors:  Neeraja Sathyamoorthy; Carol A Lange
Journal:  Horm Cancer       Date:  2020-02       Impact factor: 3.869

6.  Chemokine Signaling Facilitates Early-Stage Breast Cancer Survival and Invasion through Fibroblast-Dependent Mechanisms.

Authors:  Gage Brummer; Diana S Acevedo; Qingting Hu; Mike Portsche; Wei Bin Fang; Min Yao; Brandon Zinda; Megan Myers; Nehemiah Alvarez; Patrick Fields; Yan Hong; Fariba Behbod; Nikki Cheng
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

7.  Subcapsular transplantation of tissue in the kidney.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

Review 8.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

9.  Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype.

Authors:  Hui Li; Sara Duhachek-Muggy; Suzanne Dubnicka; Anna Zolkiewska
Journal:  Breast Cancer Res Treat       Date:  2013-06-16       Impact factor: 4.872

10.  Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.

Authors:  Laura A Petrillo; Denise M Wolf; Ann M Kapoun; Nicholas J Wang; Andrea Barczak; Yuanyuan Xiao; Hasan Korkaya; Frederick Baehner; John Lewicki; Max Wicha; John W Park; Paul T Spellman; Joe W Gray; Laura Van't Veer; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2012-09-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.